SAN DIEGO, July 27, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico participated in the LX Annual Meeting and National Congress of the Mexican Chapter of the International League Against Epilepsy, which took place in Tijuana, Mexico from July 26th to 29th.
HempMeds® Mexico provided information about cannabinoid products for the treatment of neurodegenerative conditions, such as epilepsy, as well as the results obtained by Mexican doctors using the first cannabis based treatment approved in Mexico that is the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™).
Mexican pediatric neurologist Dr. Saul Garza Morales presented information from a study involving 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period, with zero reported side effects.
“This was an incredible opportunity to meet with other doctors and discuss the latest research in the cannabinoid space,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It was wonderful to see presentations made regarding the Endogenous Cannabinoid System and view some of the emerging science behind cannabinoids and effects upon the neurological systems.”
HempMeds® Mexico is committed to educating the medical community about the therapeutic benefits of cannabinoids and to provide accurate information about its impact in the treatment of neurodegenerative diseases.
credit:otcmarkets.com
